Brief: Iconovo Develops Intranasal Semaglutide For Obesity Treatment

Iconovo AB

10/09/2024 09:36

Sept 10 (Reuters) - Iconovo AB  ICO.ST :
    * ICONOVO DEVELOPS INTRANASALLY INHALED SEMAGLUTIDE IN
ICOONE
NASAL® FOR MORE USER-FRIENDLY TREATMENT OF OVERWEIGHT AND
OBESITY
    * INITIATED DEVELOPMENT OF GLP-1 ANALOGUE SEMAGLUTIDE IN
INHALER
ICOONE NASAL FOR INTRANASAL TREATMENT OF OVERWEIGHT AND OBESITY
    * PLANS TO DEVELOP PRODUCT INTO PRECLINICAL PROOF-OF-CONCEPT
AND
SEEK PARTNERS FOR CLINICAL DEVELOPMENT

Source text for Eikon:  ID:nMFN4LR0rG 
Further company coverage:  ICO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))